

## Korea DPR Support for Pentavalent Vaccine

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> Korea DPR			
<b>2. Grant number:</b> 17-PRK-04a-X			
<b>3. Date of Decision Letter:</b> 31 October 2016 (replaces the previous Decision Letter for Pentavalent Routine dated 9 September 2015)			
<b>4. Date of the Partnership Framework Agreement:</b> 7 June 2013			
<b>5. Programme title:</b> New Vaccine Support (NVS), Pentavalent Routine			
<b>6. Vaccine type:</b> Pentavalent			
<b>7. Requested product presentation and formulation of vaccine:</b> DTP-HepB-Hib, 1 dose(s) per vial, LIQUID			
<b>8. Programme duration<sup>1</sup>:</b> 2012 – 2017			
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable)			
	2012-2016	2017	Total <sup>2</sup>
Programme Budget (US\$)	US\$11,241,338 <sup>3</sup>	US\$1,273,500	US\$ 12,514,838
<b>10. Vaccine introduction grant (in US\$):</b> Not applicable			
<b>11. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>4</sup>			
Type of supplies to be purchased with Gavi funds in each year	2012-2016	2017	
Number of Pentavalent vaccines doses		690,400	
Annual Amounts (US\$)	US\$11,241,338 <sup>5</sup>	US\$1,273,500	
<b>12. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
<b>13. Self-procurement:</b> Not applicable			

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

**14. Co-financing obligations:** Reference code: 17-PRK-04a-X-C

According to the co-financing policy, the Country falls within the Initial Self Financing group.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2017
Number of vaccine doses	84,000
Number of AD syringes	
Number of re-constitution syringes	
Number of safety boxes	
Value of vaccine doses (US\$)	US\$149,066
Total co-financing payments (US\$) (including freight)	US\$155,000

**15. Operational support for campaigns:** Not applicable

**16. Additional reporting requirements:** Not applicable

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

**17. Financial clarifications:** Country shall provide the following clarifications to Gavi\*:  
Not applicable

*\*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements*

**18. Other conditions:** Not applicable

Signed by,



**On behalf of Gavi**

Hind Khatib-Othman  
Managing Director, Country Programmes  
31 October 2016